Moderna shares surge after it says experimental mRNA cancer treatment passed key test
Summary
Moderna’s stock price more than doubled after the company announced positive early results from a study of its new mRNA cancer vaccine called intismeran. When combined with Merck’s immunotherapy drug Keytruda, the treatment helped melanoma patients live longer without their cancer returning compared to Keytruda alone.Key Facts
- Moderna shares rose sharply following the study announcement.
- The treatment, intismeran, is an mRNA cancer vaccine tailored to each patient’s tumor mutations.
- Moderna is working with Merck, which makes the immune-boosting drug Keytruda.
- The study tested intismeran plus Keytruda against Keytruda alone in melanoma patients.
- Patients receiving both drugs lived longer without cancer coming back or spreading.
- This treatment would be the first of its kind if approved by health regulators.
- mRNA vaccines use genetic material to instruct the body to fight disease, similar to some COVID-19 vaccines.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
